{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:36:23Z","timestamp":1794314183716,"version":"4.9.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite traditional therapy of a diuretic, angiotensin converting enzyme inhibitor, digoxin, or a combination of these drugs, survival of dogs with dilated cardiomyopathy (DCM) is low. Pimobendan, an inodilator, has both inotropic and balanced peripheral vasodilatory properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>Pimobendan when added to conventional therapy will improve morbidity and reduce case fatality rate in Doberman Pinschers with congestive heart failure (CHF) caused by DCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Sixteen Doberman Pinschers in CHF caused by DCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective randomized, double-blind, placebo-controlled study with treatment failure as the primary and quality of life (QoL) indices as secondary outcome variables. Therapy consisted of furosemide (per os [PO] as required) and benazepril hydrochloride (0.5\u2003mg\/kg PO q12h) and dogs were randomized in pairs and by sex to receive pimobendan (0.25\u2003mg\/kg PO q12h) or placebo (1 tablet PO q12h).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pimobendan-treated dogs had a significant improvement in time to treatment failure (pimobendan median, 130.5 days; placebo median, 14 days; P= .002; risk ratio = 0.35, P= .003, lower 5% confidence limit = 0.13, upper 95% confidence limit = 0.71). Number and rate of dogs reaching treatment failure in the placebo group precluded the analysis of QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Pimobendan should be used as a first-line therapeutic in Doberman Pinschers for the treatment of CHF caused by DCM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2008.0116.x","type":"journal-article","created":{"date-parts":[[2009,1,22]],"date-time":"2009-01-22T11:12:46Z","timestamp":1232622766000},"page":"897-904","source":"Crossref","is-referenced-by-count":66,"title":["Effect of Pimobendan on Case Fatality Rate in Doberman Pinschers with Congestive Heart Failure Caused by Dilated Cardiomyopathy"],"prefix":"10.1093","volume":"22","author":[{"given":"M.R.","family":"O'Grady","sequence":"first","affiliation":[{"name":"the Ontario Veterinary College, University of Guelph, Guelph Department of Clinical Studies, , ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Minors","sequence":"additional","affiliation":[{"name":"Mississauga-Oakville Veterinary Emergency Hospital and Referral Group, Oakville , ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"O'Sullivan","sequence":"additional","affiliation":[{"name":"the Ontario Veterinary College, University of Guelph, Guelph Department of Clinical Studies, , ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Horne","sequence":"additional","affiliation":[{"name":"the Ontario Veterinary College, University of Guelph, Guelph Department of Clinical Studies, , ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,7,1]]},"reference":[{"key":"2026020304232066000_b1","first-page":"995","volume-title":"Textbook of Veterinary Internal Medicine. Diseases of the Dog and Cat","author":"Sisson","year":"1995","edition":"4th ed"},{"key":"2026020304232066000_b2","first-page":"647","volume-title":"Current Veterinary Therapy XI","author":"Buchanan","year":"1992"},{"key":"2026020304232066000_b3","first-page":"756","volume-title":"Current Veterinary Therapy XIII","author":"Calvert","year":"2000"},{"key":"2026020304232066000_b4","first-page":"114","author":"O'Grady","year":"2002"},{"key":"2026020304232066000_b5","first-page":"1187","article-title":"Dilated cardiomyopathy","volume":"34","author":"O'Grady","year":"2004","journal-title":"An update"},{"key":"2026020304232066000_b6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1939-1676.1997.tb00474.x","article-title":"Signalment, survival, and prognostic factors in Doberman Pinschers with end-stage cardiomyopathy","volume":"11","author":"Calvert","year":"1997","journal-title":"J Vet Int Med"},{"key":"2026020304232066000_b7","first-page":"243","article-title":"Controlled clinical evaluation of enalapril in dogs with heart failure","volume":"9","author":"The COVE Study Group","year":"1995","journal-title":"Results of the Cooperative Veterinary Enalapril Study Group"},{"key":"2026020304232066000_b8","first-page":"234","article-title":"Acute and short-term hemodynamics, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure","volume":"9","author":"The IMPROVE Study Group","year":"1995","journal-title":"Results of the Invasive Multicenter Prospective Veterinary Evaluation of Enalapril Study"},{"key":"2026020304232066000_b9","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2460\/javma.1998.213.11.1573","article-title":"Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group","volume":"213","author":"Ettinger","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304232066000_b10","first-page":"7","article-title":"The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure","volume":"1","author":"The BENCH (Benazepril Hydrochloride in Canine Heart Disease) Study Group","year":"1999","journal-title":"Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial"},{"issue":"4","key":"2026020304232066000_b11","first-page":"S1","article-title":"Hemodynamic profile of the cardiotonic agent pimobendan","volume":"14","author":"Van Meel","year":"1989","journal-title":"J Cardiovasc Pharm"},{"key":"2026020304232066000_b12","first-page":"911","article-title":"Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan","volume":"63","author":"Fujino","year":"1988","journal-title":"Comparison with milrinone"},{"issue":"4","key":"2026020304232066000_b13","first-page":"S18","article-title":"Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure","volume":"14","author":"Pouleur","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026020304232066000_b14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00227906","article-title":"Phosphodiesterase inhibition and Ca2+ sensitization","volume":"157","author":"Ravens","year":"1996","journal-title":"Mol Cell Biochem"},{"key":"2026020304232066000_b15","first-page":"H1699","article-title":"Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure","volume":"276","author":"Sato","year":"1999","journal-title":"Am J Physiol"},{"key":"2026020304232066000_b16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/eurheartj\/14.4.551","article-title":"Calcium sensitization with pimobendan; pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure","volume":"14","author":"Hagemeijer","year":"1993","journal-title":"Eur Heart J"},{"key":"2026020304232066000_b17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0014-2999(86)90733-8","article-title":"Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties","volume":"126","author":"Verdouw","year":"1986","journal-title":"Eur J Pharmacol"},{"key":"2026020304232066000_b18","first-page":"317","article-title":"Effect of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure","volume":"33","author":"Sasaki","year":"1999","journal-title":"J Cardio"},{"key":"2026020304232066000_b19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/eurheartj\/12.8.889","article-title":"Comparison of hormonal and hemodynamic changes after long-term therapy with pimobendan or enalapril\u2014A double-blind randomised study","volume":"12","author":"Erlemeier","year":"1991","journal-title":"Eur Heart J"},{"key":"2026020304232066000_b20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/00005344-198913050-00008","article-title":"Cardiovascular profile of UD-CG 115BS\u2014Pimobendan and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idopathic dilated cardiomyopathy","volume":"13","author":"Baumann","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026020304232066000_b21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00005344-199402000-00014","article-title":"Disparate inotropic and lusitropic response to pimobendan in conscious dogs with tachycardia-induced heart failure","volume":"23","author":"Asanoi","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026020304232066000_b22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/S0735-1097(98)00692-5","article-title":"Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis","volume":"33","author":"Iwasaki","year":"1999","journal-title":"J Am Coll Cardio"},{"key":"2026020304232066000_b23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1939-1676.2002.tb02366.x","article-title":"A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy","volume":"16","author":"Fuentes","year":"2002","journal-title":"J Vet Int Med"},{"key":"2026020304232066000_b24","first-page":"104","author":"Lombard","year":"2003"},{"key":"2026020304232066000_b25","first-page":"97","author":"Lombard","year":"2004"},{"key":"2026020304232066000_b26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1253\/circj.66.149","article-title":"Effects of pimobendan on adverse cardiac events and physical activities in patients with mild-to-moderate heart failure\u2014The effects of pimobendan on chronic heart failure study","volume":"66","author":"The EPOCH Study Group","year":"2002","journal-title":"Circ J"},{"key":"2026020304232066000_b27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1748-5827.2005.tb00302.x","article-title":"Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease","volume":"46","author":"Smith","year":"2005","journal-title":"J Small Anim Pract"},{"key":"2026020304232066000_b28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5326\/0420249","article-title":"Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs","volume":"42","author":"Lombard","year":"2006","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020304232066000_b62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2460\/javma.1995.206.02.194","article-title":"Vertebral scale system to measure canine heart size in radiographs","volume":"206","author":"Buchanan","year":"1995","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304232066000_b30","first-page":"551","volume-title":"Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine","author":"Givertz","year":"2005","edition":"7th ed"},{"key":"2026020304232066000_b31","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"2026020304232066000_b32","first-page":"223","article-title":"Efficacy of pimobendan on exercise capacity in patients with heart failure","volume":"76","author":"Lubsen","year":"1996","journal-title":"Main results from the pimobendan in congestive heart failure (PICO) trial"},{"key":"2026020304232066000_b33","first-page":"606","article-title":"Survival Analysis Part III","volume":"89","author":"Bradburn","year":"2003","journal-title":"Multivariate data analysis\u2014Choosing a model and assessing its adequacy and fit"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2008.0116.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/4\/897\/66674036\/j.1939-1676.2008.0116.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/4\/897\/66674036\/j.1939-1676.2008.0116.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:23:33Z","timestamp":1770110613000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/22\/4\/897\/8449995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2008.0116.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,7]]},"published":{"date-parts":[[2008,7,1]]}}}